Increased	O
serum	B-Organism_substance
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
in	O
patients	O
with	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
.	O

Neovascularization	O
,	O
an	O
essential	O
event	O
for	O
the	O
growth	O
of	O
solid	B-Cancer
tumors	I-Cancer
,	O
is	O
regulated	O
by	O
a	O
number	O
of	O
angiogenic	O
factors	O
.	O

One	O
such	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
is	O
considered	O
to	O
exert	O
a	O
potent	O
angiogenic	O
activity	O
,	O
as	O
indicated	O
by	O
immunohistochemical	O
and	O
molecular	O
evidence	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
serum	B-Organism_substance
VEGF	O
level	O
(	O
s	O
-	O
VEGF	O
)	O
in	O
patients	O
with	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
(	O
RCC	B-Cancer
)	O
.	O

s	O
-	O
VEGF	O
in	O
peripheral	B-Organism_substance
blood	I-Organism_substance
samples	I-Organism_substance
was	O
analyzed	O
in	O
40	O
RCC	B-Cancer
patients	O
and	O
40	O
patients	O
without	O
cancer	B-Cancer
(	O
controls	O
)	O
using	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

In	O
20	O
RCC	B-Cancer
patients	O
,	O
serum	B-Organism_substance
samples	I-Organism_substance
were	O
obtained	O
separately	O
from	O
the	O
bilateral	B-Multi-tissue_structure
renal	I-Multi-tissue_structure
veins	I-Multi-tissue_structure
.	O

s	O
-	O
VEGF	O
was	O
also	O
measured	O
before	O
,	O
4	O
and	O
8	O
weeks	O
after	O
nephrectomy	O
in	O
11	O
patients	O
.	O

There	O
were	O
significant	O
differences	O
in	O
s	O
-	O
VEGF	O
between	O
the	O
RCC	B-Cancer
patients	O
and	O
the	O
controls	O
(	O
207	O
.	O
3	O
+	O
/	O
-	O
32	O
.	O
9	O
vs	O
.	O
71	O
.	O
5	O
+	O
/	O
-	O
9	O
.	O
1	O
pg	O
/	O
ml	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
between	O
the	O
tumor	B-Cancer
-	O
bearing	O
renal	B-Multi-tissue_structure
veins	I-Multi-tissue_structure
and	O
the	O
contralateral	O
ones	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
between	O
the	O
pre	O
-	O
and	O
post	O
-	O
nephrectomy	O
situations	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
among	O
the	O
various	O
parameters	O
of	O
tumor	B-Cancer
status	O
such	O
as	O
tumor	B-Cancer
extent	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
existence	O
of	O
metastasis	B-Cancer
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

s	O
-	O
VEGF	O
significantly	O
correlated	O
with	O
the	O
tumor	B-Cancer
volume	O
obtained	O
by	O
a	O
three	O
-	O
dimensional	O
measurement	O
(	O
r	O
=	O
0	O
.	O
802	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
s	O
-	O
VEGF	O
at	O
the	O
cut	O
-	O
off	O
level	O
of	O
100	O
pg	O
/	O
ml	O
,	O
as	O
determined	O
by	O
the	O
receiver	O
-	O
operating	O
-	O
characteristics	O
curve	O
,	O
were	O
80	O
.	O
0	O
%	O
and	O
72	O
.	O
5	O
%	O
,	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
tumor	B-Tissue
tissue	I-Tissue
of	O
RCC	B-Cancer
liberates	O
VEGF	O
into	O
the	O
systemic	O
blood	B-Organism_substance
flow	O
and	O
that	O
s	O
-	O
VEGF	O
is	O
a	O
possible	O
marker	O
for	O
RCC	B-Cancer
.	O

